Skip to content

The Effect of Theraworx Foam in Carpal Tunnel Syndrome

The Effect of Theraworx Foam on the Cross-sectional Area of the Median Nerve in Patients With Carpal Tunnel Syndrome

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04017390
Enrollment
0
Registered
2019-07-12
Start date
2022-01-01
Completion date
2022-01-03
Last updated
2022-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carpal Tunnel Syndrome

Keywords

Hand Pain/Numbness

Brief summary

Participation will be for approximately 21 days (3 study visits,1 week apart with allowance for scheduling conflicts). A topical (or placebo) foam alone or with a splint will be used. Demographic and symptom information will be obtained. At each visit 3 questionnaires (BCT, CTS-6, and DASH) will be completed and an ultrasound of the wrist (median nerve) will be done to document any change in symptoms and/or in the size of the nerve. Random assignment will be to one of 4 groups: foam or placebo with or without a night splint. We will provide instruction on how to apply the foam, whether or not and how to wear the splint, and return visits.

Detailed description

The PI will identify potential participants from his clinical practice. Evaluation of symptoms will be by exam, questionnaires, and ultrasound of the median nerve. These will document baseline/change in the size of the median nerve and improvement in function/symptoms. The questionnaires are 1.) Boston Carpal Tunnel (BCT). 2.) Carpal Tunnel-6 (CTS-6); and 3.) Disabilities of the Arm, Shoulder and Hand (DASH). These will be used to document a baseline and change (if any) in nerve size and hand symptoms, over a 2 week time frame, that are common in carpal tunnel syndrome (including numbness, pain, tingling, and/or decreased function). 1. The Boston Carpal Tunnel is a 19 question tool that assesses function (8 items) and symptom severity (11 items). Score range is from 0 to 95 with a high number indicating more severe/worsening symptoms and lower number less severe/improving symptoms. 2. The CTS-6 is a six item tool that combines reported symptoms with a physical exam of the hand. Scores range from 0 to 26 with a higher score reflecting increased severity. 3. The DASH is a 30 item tool with each scored 1 to 5. Scores can range from 0 to 150 and the higher the score the worse the symptoms/disability. Treatment groups are as follows:1.) Theraworx foam alone; 2.) Theraworx foam with night time splint; 3.) Placebo foam alone; 4.) Placebo foam with night time splint. The active ingredient in Theraworx foam is magnesium sulfate and will not be in the placebo foam. Instructions on how to apply the foam, whether or not and how to wear the splint, and return visits will be provided. If in a group that requires night time splinting, the subject must wear the splint only at night and for a minimum of 8 hours.

Interventions

DRUGTheraworx Foam

Apply Theraworx Foam alone

Apply placebo foam alone

OTHERTheraworx Foam and night splint

Apply Theraworx Foam and night time splint

OTHERPlacebo Foam and night time splint

Apply placebo foam and night time splint

Sponsors

Avadim Technologies, Inc.
CollaboratorINDUSTRY
John Fowler
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Intervention model description

Randomization will be to one of four groups: 1.) Theraworx foam alone; 2.) Theraworx foam plus night time splint; 3.) Placebo foam alone; 4.) Placebo foam plus night time splint. Theraworx Foam is an FDA registered (NDC 61594-001-02) topical agent (active ingredient: magnesium sulfate superficia 6 x 0.05% HPUS) for muscle cramp and spasm relief.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of Carpal Tunnel Syndrome * Age 18 years or older * Interest in non-surgical treatment of carpal tunnel syndrome

Exclusion criteria

* Prior carpal tunnel release * Non-English speaking * Skin lesions/rashes on hand being treated * Current use of topical anti-inflammatory medication * Other diagnoses that would impact results (determined by PI)

Design outcomes

Primary

MeasureTime frameDescription
Improvement (decrease) in size of median nerve at the wrist2 weeksDecrease in cross sectional area of median nerve as determined by ultrasound exam

Secondary

MeasureTime frameDescription
Improvement (decrease) in Boston Carpal Tunnel Questionnaire (BCTQ)2 weeksImprovement in PRO as indicated by a decreased score on questionnaire indicating improved in function and decreased symptoms
Improvement (decrease) in Carpal Tunnel 6 (CTS-6) score2 weeksImprovement in patient reported outcome (PRO) as determined by a lower CTS-6 score number than at baseline. Score ranges from 26 (worst) to 0 (best)
Improvement (decrease) in Disabilities of Arm, Shoulder, Hand (DASH) score2 weeksImprovement in patient reported outcome (PRO) as determined by decreased DASH score from baseline. Score ranges from 150 (worst) to 30 (best)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026